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Although the outcomes of unilateral Wilms tumors have greatly improved and few survivors experience serious late onset health issues, patients with bilateral Wilms tumors (BWT) have serious renal late effects from the treatments if renal tissue cannot be preserved [1] [2] [3] [4] [5] ; therefore, the treatment of BWT is still challenging. The most important concern is preserving renal function and leaving the maximum amount of normal renal parenchyma while maximally resecting the renal tumors to eliminate the risk of recurrence. Every patient needs tailored decisions on whether to intensify or prolong chemotherapy, as well as on the timing or type of surgery. of renal parenchyma. The results from international and national study groups have helped to draw some guidelines for this specific group of patients. [6] [7] [8] [9] [10] [11] [12] The Turkish Pediatric Oncology Group (TPOG) has been conducting a study on renal tumors since 1998 based on the principles of the SIOP-93 regimen. The TPOG group reported the treatment results from unilateral WTs 13 and the outcomes of surgery for BWT. 14 In this study, the outcome of BWT patients from a single center who were treated by the TPOG Wilms tumor regimen were retrospectively reviewed.
Material and Methods
From January 1990 to July 2016, 303 patients with Wilms tumors were treated in our center. Among this group, 30 consecutive patients with synchronous BWT were treated. The hospital files and medical records for these patients were retrospectively reviewed and evaluated for this study. All patients were evaluated with at least two different radiological examinations of the abdomen: with ultrasound (US) and either computed tomography (CT) or magnetic resonance imaging (MR). The metastatic evaluation was primarily based on posterior, anterior and lateral chest X-rays, but thoracic CT was added to the metastatic workup if visible lung metastases were detected. All patients were discussed by an institutional multidisciplinary tumor board consisting of pediatric oncologists, pediatric surgeons, pediatric pathologists, pediatric radiologists and pediatric radiation oncologists; the board first discussed the initial radiological findings for staging and later discussed evaluation of the response to preoperative treatment and surgical interventions using additional radiological findings.
Preoperative chemotherapy consisted of vincristine and actinomycin-D (VA). The details of the regimen are given in Table I . Chemotherapy consisted of vincristine (V) (1.5 mg/m 2 , D1 and then weekly for 4 weeks) and actinomycin-D (A) (15 µg/kg/day, D1, D2, D3, D4 and D5). At the 5 th week, abdominal US and CT scans were performed to evaluate the patients' response, then each patient's case was discussed by the tumor board in preparation for the initial surgery. If the tumors responded and the tumor volume decreased, but nephronsparing surgery (NSS) was not possible, a second cycle of the VA regimen was given, and a radiological evaluation was repeated at the end of it. At the end of the second cycle, the patients were discussed by the tumor board to decide on surgery strategies. If the tumors regressed and bilateral NSS were possible, patients underwent surgery, and further treatment was planned with postoperative staging and histopathological findings (Table I) . Otherwise, preoperative chemotherapy was continued, depending on the response, either with the VA regimen (if tumor volume continued to decrease) or the VAD regimen (if the tumor was stable), which was intensified by adding doxorubicin (D) (20 mg/m 2 , D1, D2 and D3 alternating with VA in every 6 weeks). Chemotherapy was continued until a safe NSS could be performed, as long as the tumor continued to respond to radiological intervention.
If possible, surgery was performed on both kidneys during the same operation, and the goal was bilateral NSS. Unless it was necessary, bilateral radical nephrectomies (RN) were avoided in all patients. NSS was defined as a partial nephrectomy with negative tumor margins and enucleation of the tumor. A unilateral RN was performed if the kidney had little tumor-free parenchyma. Biopsy or tumor resection were considered for tumors that showed no response to chemotherapy after intensification. Additional radiological tests were performed to show the renal anatomy and vascular structures for precise surgery if needed.
All the patients who survived periodically followed up to check renal function. Blood pressure, serum creatinine and BUN levels, urine glomerular filtration rates (GFR), and urinary protein excretion were checked in routine controls.
The time intervals for survival parameters started at the time of admission and were measured to the date of relapse, to progression of event free survival (EFS), to death, until the last contact, or when the patient met the study endpoint of overall survival (OS Table III . Six patients underwent two procedures for tumor resection. Three of them had an RN in the first session then NSS in the second operation (one partial nephrectomy and two enucleation). These three patients are still followed with no evidence of disease at 262, 25 and 29 months, respectively. Two patients had a partial nephrectomy and enucleation at the first session and a partial nephrectomy and enucleation at second session; they are well with no relapse at 297 and 52 months of follow-up. One patient had bilateral renal biopsies. This patient had bilateral RN for bilateral anaplasia noted on the tumor biopsies, and he died of renal failure with underlying cardiomyopathy and heart failure.
Four patients had no surgery on the contralateral kidney since the tumors had disappeared on their preoperative radiological images and inspection during surgery confirmed the radiological findings. These patients have been relapse-free for 42, 117, 270 and 297 months. In another two patients, the intraoperative biopsies of residual lesions showed no tumor. These tumors were staged as stage I tumors, and further treatment was planned based on other renal tumors if they had higher stage of tumor. Histopathological examination showed unfavorable histology (UH) in eight tumors from six patients (20%). Anaplasia was diagnosed in seven tumors from six patients, and blastemal histology was found in one tumor. Nephrogenic rests were reported in six patients (20%). The 5-year OS and EFS rates were 50% and 25%, respectively, in patients with anaplasia, while the same rates were 96% and 96% in patients with FH tumors (p=0.05 and p<0.001). Survival rates are shown in Figure 1a . Three patients with unresponsive tumors showed anaplasia, another four had cystic partially differentiated nephroblastoma or epithelial Wilms tumors.
The 10-year OS and EFS rates for all patients were 86% and 82%, respectively (Fig. 1b) . The 5-year EFS rates for patients with stages I, II and III were 100%, 90% and 51%, respectively (p=0.02) (Fig. 1c ). The 5-year OS rates were 100%, 90% and 63% for stages I, II and III, respectively (p=0.08). Only one patient died immediately after surgery due to cardiac and renal failure. This patient had bilateral anaplasia at initial needle biopsies and had to undergo bilateral RN and dialysis. She previously had hypertensive cardiomyopathy and died shortly after surgery. None of the patients who survived currently have renal failure. All patients had a GFR>60 mL/min/1.73 m 2 at last follow-up.
Discussion
Synchronous bilateral Wilms tumors need special consideration when treating them. International collaborative studies have been shaping the principles of treatment, and the outcome has greatly improved over the last few decades. [6] [7] [8] [9] [10] 11, 15 It is critical that these principles and results be reproducible in other centers. Therefore, we presented the treatment and results of BWT in our center. The long-term EFS of 82% and OS of 86% were analogous with other single or multicenter groups. The only discrepancy in this series of patients with BWT was the higher prevalence rate of 9.9%, even compared to the previously reported results from TPOG. 7, 8, [10] [11] [12] [13] Our center is one of the largest and most experienced pediatric cancer centers, and the higher prevalence might be a reflection of the high referral rate of difficult cases. Other demographic features such as gender, median age, UH or genetic syndromes were consistent with literature. Nephrogenic rests were found in 6 children, higher than expected for unilateral tumors (20%). Unfavorable histology in at least one kidney was detected in 6 of the children (20%). UH was a poor prognostic factor as reported in other studies. [10] [11] [12] 15, 16 The 5-year OS and EFS rates in patients with UH were 50% and 25%, respectively, which is worse than patients with FH tumors.
A median preoperative chemotherapy duration of 11.6 weeks produced 64% of stage I tumors.
Although some patients needed as long as 30 weeks to have a safe resection, 57% of the children had tumor removal within 3 months. Bilateral NSS were performed in 6 patients (20%). Some studies suggest that 12 weeks is the optimum duration for preoperative chemotherapy to allow for a complete and safe NSS. 10, 11 Although NSS leaves functioning renal parenchyma, there is always the risk of leaving positive tumor margins, especially for the multifocal tumors. The major concern with microscopic residual tumors is the risk of local or distant relapses and chemotherapy intensification and/or RT is then needed for the local control. There are reports that microscopic residue might not increase the recurrence rate. 17 In this series of patients, there were 3 kidneys with positive microscopic margins in our group, and RT was not given due to multiple tumors. All three tumors had favorable histology and intensification of chemotherapy seemed to control the residual microscopic disease. In addition, 6 tumors disappeared completely with preoperative chemotherapy, and all have been well and off-therapy, with no evidence of tumor. Our experience supports this comment. However, evidence is scarce and microscopic residue after surgery should be discussed cautiously. Fig. 1. a The outcome and treatment success has tremendously improved for WT over the past few decades, and BWT followed this improvement. The SIOP studies showed that preoperative chemotherapy enabled the surgeons to perform safe surgeries and preserve the maximum amount of renal parenchyma. Preoperative chemotherapy has been the backbone in the treatment of BWT since then. There are differences in the contents and duration of preoperative regimens. SIOP and SIOP-like regimens consist of two drugs: vincristine and actinomycin. 11 There are reports doxorubicin was added to VA (VAD) as initial treatment in selected cases. 10 The AEIOP group reported that the VAD regimen seemed to produce a better local control rate. However, VA and VAD produced similar treatment outcomes and the outcome difference was statistically insignificant. 10 The physician chose whether to use the VAD regimen; the decision was not made based on previously determined criteria or the presence of high-risk features of the tumors. Therefore, it is not easy to conclude whether a more intensive regimen warrants better outcomes.
In our series of patients, 10/30 patients received treatment with VA only, and all were long-term survivors, suggesting not all patients with BWT need an intensive regimen upfront. It should also be considered that some patients did not need doxorubicin at all. If a preoperative VAD regimen enables better local control, this should be reflected in the survival gain.
The only limitation of this study is its retrospective manner. Although patients were intended to be treated from the time of diagnosis, the evaluation had to be done retrospectively due to its small numbers. Quite a number of published studies are done retrospectively due to the small number of patients with BWT and because their treatments are heterogeneous, even in the same center.
Ongoing prospective studies with cumulative results from centers will address the effect of a more intensified preoperative chemotherapy on outcomes.
